FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 325 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR FDA Approves Lutetium Lu 177 Dotatate for Paediatric Patients 12 Years... May 15, 2024 FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma February 7, 2022 Assessment of Patients’ Perspective on the Consequences of the COVID-19 Pandemic... July 16, 2020 Estimate of the Global Economic Cost of the Most Prevalent Cancers... March 13, 2023 Load more HOT NEWS 3-Year-Old Boy Receives Hundreds Of Sweet Birthday Cards In The Mail... Young Woman Considers Service Dog A Crucial Ally In Her Battle... Change Your Thoughts, Change Your World Flame of Hope Awards: Celebrating our volunteers
